The 4th Systemic Sclerosis World Congress will take place in Lisbon, Portugal, from 18th to 20th February and Scleroderma News will be covering the whole event. Even though this is a systemic sclerosis (SSc) congress, a lot will be discussed about pulmonary arterial hypertension (PAH), which is considered a leading cause of mortality among systemic scleroderma patients.
Therefore, we decided to chose one article per satellite symposium that Scleroderma News team is planning to cover. Here are the articles:
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress.